ArticleEuropean heart journal. Case reports2025
Breast cancer surgery under mechanical circulatory support in a patient with cancer therapy-related cardiac dysfunction: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanical circulatory support as a bridge to cancer therapy in patients with end stage heart failure: a single center experience.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of cancer therapy-related cardiac dysfunction is increasing with the growing number of breast cancer patients. In particular, patients with active cancer combined with severe irreversible cardiac dysfunction present significant challenges in treatment decision-making. Case summary: A 40-year-old woman with Stage II HER-2-positive breast cancer received anthracycline followed by HER2-targeted agents. She developed severe heart failure due to cancer therapy-related cardiac dysfunction, with haemodynamic instability necessitating mechanical circulatory support using percutaneous cardiopulmonary support and Impella 5.5. Several weaning attempts of Impella 5.5 failed. Due to limitation for the duration of Impella support, right breast tumour resection and axillary lymph node dissection were performed under ongoing Impella support. The procedure was completed without surgical complications including significant bleeding. The patient was transferred to a specialized cardiovascular institution for possible left ventricular assist device evaluation. Discussion: This case report provides valuable insight into treatment decision-making in complex cases of irreversible cancer therapy-related cardiac dysfunction, where both oncologic and cardiologic considerations must be balanced under time-limited support devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.